Treatment of pediatric-onset multiple sclerosis Review article
Article Sidebar
Published:
Jun 30, 2024
Keywords:
pediatric multiple sclerosis, therapy, treatment
Main Article Content
Abstract
Multiple sclerosis is a rare pediatric-population inflammation and neurodegeneration disease with a high impact to a neurological condition and quality of life. An aggressive course of the disease in young patient’s population determines a necessity of a fast start and effective treatment. The Therapeutic Program of the Multiple Sclerosis Treatment is the main way of the pediatric’s patients treatment in Poland. It is possible to choose several drugs: interferons beta, glatiramer acetate, teriflunomide, dimethyl fumarate or, in case of a rapid progress of the disease – fingolimod or natalizumab. The more often a high-efficacy therapy is taken under consideration instead of an escalation model of the therapy. A good cooperation with the patient and parents is the main condition of the therapies’ success.
Article Details
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bigi S, Banwell B. Pediatric Multiple Sclerosis. J Child Neurol. 2012; 27: 1378-83.
2. Renoux C, Vukusic S, Convavreux C et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007; 356(25): 2603-13.
3. Trojano M, Paolicelli D, Bellacosa A et al. Atypical forms of multiple sclerosis or diffrent phases of a same disease? Neurol Sci. 2004; 25(S4): 323-5.
4. Gorman MP, Healy BC, Polgar-Turscanyi M et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009; 66 (1): 54-9.
5. Yeh EA, Weinstock-Guttman B, Ramanathan M et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009; 132(12): 3392-400.
6. Ruggieri M, Ianetti P, Polizzi A et al. Multiple sclerosis in children under 10 years of age. Neurol Sci. 2004; 25(Suppl 4): S326-35.
7. Wallach AI, Waltz M, Casper TC et al. Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Mult Scler. 2020; 26(14): 1938-47.
8. Brola W, Steinborn B, Niewiada M et al. Pediatric-onset multiple sclerosis in Poland: A registry-based retrospective cohort study. Mult Scler Relat Disord. 2022; 57: 103344.
9. Chitnis T, Tenembaum S, Banwell B et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosi. Mult Scler J. 2012; 18(1):116-27.
10. Chitnis T, Tardieu M, Amato MP et al. International pediatric MS study group clinical trials summit: meeting report. Neurology. 2013; 80(12): 1161-8.
11. Colligan E, Metzler A, Tiryaki E et al. Shared decision-making in multiple sclerosis. Mult Scler. 2017; 23(2): 185-90.
12. Leczenie chorych na stwardnienie rozsiane (ICD-10: G35) – Załącznik B.29.
13. Wong YYM, de Mol CL, van der Vuurst de Vries RM et al. Real-world validation of the 2017 McDonald criteria for diagnosis pediatric MS. Neurol Neuroimmunol Neuroinflamm. 2019; 6(2): e528.
14. Banwell B. Pediatric multiple sclerosis: The 2022 ECTRIMS lecture Mult Scler J. 2023; 29(7): 772-8.
15. Chitnis T, Banwell B, Kappos L et al. Safety and efficacyof teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021; 20(12): 1001-11.
16. Alroughani R, Das R, Penner R et al. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple-sclerosis (FOCUS). Pediatr Neurol. 2018; 83: 19-24.
17. Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M et al. Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsin-remitting multiple sclerosis. Front Neurol. 2020; 11: 606418.
18. Chitnis T, Arnold DL, Banwell B et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018; 379(11): 1017-27.
19. Ghezzi A, Maiola L, Pozzilli C et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015; 15: 174.
20. Otero-Romero S, Lebrun-Frenay C, Reyes S et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs Mult Scler J. 2023; 29(8): 904-25.
21. McGinley M, Rossman I. Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis Neurotherap. 2017; 14: 985-98.
22. Sandesjo F, Wassmer E, Deiva K et al. Current international trends in the treatment of multiple sclerosis in children – Impact od the COVID-19 pandemic. Mult Scler Relat Disord. 2021; 56: 103277.
23. Duffy L, Sarill K, Forbes P et al. Shared Decision Making and Disease Modyfying Therapy in Families of Children and Adolescents with Pediatric Onset Multiple Sclerosis. J Ped Nurs. 2021; 61: P404-9.
2. Renoux C, Vukusic S, Convavreux C et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med. 2007; 356(25): 2603-13.
3. Trojano M, Paolicelli D, Bellacosa A et al. Atypical forms of multiple sclerosis or diffrent phases of a same disease? Neurol Sci. 2004; 25(S4): 323-5.
4. Gorman MP, Healy BC, Polgar-Turscanyi M et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol. 2009; 66 (1): 54-9.
5. Yeh EA, Weinstock-Guttman B, Ramanathan M et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain. 2009; 132(12): 3392-400.
6. Ruggieri M, Ianetti P, Polizzi A et al. Multiple sclerosis in children under 10 years of age. Neurol Sci. 2004; 25(Suppl 4): S326-35.
7. Wallach AI, Waltz M, Casper TC et al. Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Mult Scler. 2020; 26(14): 1938-47.
8. Brola W, Steinborn B, Niewiada M et al. Pediatric-onset multiple sclerosis in Poland: A registry-based retrospective cohort study. Mult Scler Relat Disord. 2022; 57: 103344.
9. Chitnis T, Tenembaum S, Banwell B et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosi. Mult Scler J. 2012; 18(1):116-27.
10. Chitnis T, Tardieu M, Amato MP et al. International pediatric MS study group clinical trials summit: meeting report. Neurology. 2013; 80(12): 1161-8.
11. Colligan E, Metzler A, Tiryaki E et al. Shared decision-making in multiple sclerosis. Mult Scler. 2017; 23(2): 185-90.
12. Leczenie chorych na stwardnienie rozsiane (ICD-10: G35) – Załącznik B.29.
13. Wong YYM, de Mol CL, van der Vuurst de Vries RM et al. Real-world validation of the 2017 McDonald criteria for diagnosis pediatric MS. Neurol Neuroimmunol Neuroinflamm. 2019; 6(2): e528.
14. Banwell B. Pediatric multiple sclerosis: The 2022 ECTRIMS lecture Mult Scler J. 2023; 29(7): 772-8.
15. Chitnis T, Banwell B, Kappos L et al. Safety and efficacyof teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021; 20(12): 1001-11.
16. Alroughani R, Das R, Penner R et al. Safety and efficacy of delayed-release dimethyl fumarate in pediatric patients with relapsing multiple-sclerosis (FOCUS). Pediatr Neurol. 2018; 83: 19-24.
17. Alroughani R, Huppke P, Mazurkiewicz-Beldzinska M et al. Delayed-release dimethyl fumarate safety and efficacy in pediatric patients with relapsin-remitting multiple sclerosis. Front Neurol. 2020; 11: 606418.
18. Chitnis T, Arnold DL, Banwell B et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018; 379(11): 1017-27.
19. Ghezzi A, Maiola L, Pozzilli C et al. Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol. 2015; 15: 174.
20. Otero-Romero S, Lebrun-Frenay C, Reyes S et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs Mult Scler J. 2023; 29(8): 904-25.
21. McGinley M, Rossman I. Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis Neurotherap. 2017; 14: 985-98.
22. Sandesjo F, Wassmer E, Deiva K et al. Current international trends in the treatment of multiple sclerosis in children – Impact od the COVID-19 pandemic. Mult Scler Relat Disord. 2021; 56: 103277.
23. Duffy L, Sarill K, Forbes P et al. Shared Decision Making and Disease Modyfying Therapy in Families of Children and Adolescents with Pediatric Onset Multiple Sclerosis. J Ped Nurs. 2021; 61: P404-9.